#1 Clinical Trials Search in Europe

Octreotide

Octreotide, a synthetic analog of somatostatin, is being studied in clinical trials for its potential benefits in treating various medical conditions. These trials aim to evaluate the efficacy and safety of octreotide in managing symptoms, improving quality of life, and potentially slowing disease progression in conditions such as neuroendocrine tumors, gastrointestinal disorders, and certain genetic diseases. This article explores the current landscape of octreotide research and its potential applications in medical treatment.

Table of Contents

What is Octreotide?

Octreotide is a medication that belongs to a class of drugs called somatostatin analogs. It is a synthetic version of a naturally occurring hormone in the body called somatostatin. Octreotide is known by various brand names, including Sandostatin, Sandostatin LAR, and Siroctid[1][2]. This medication is used to treat several conditions related to hormone imbalances and certain types of tumors.

Conditions Treated with Octreotide

Octreotide is used to treat a variety of medical conditions, including:

  • Acromegaly: A condition where the body produces too much growth hormone, leading to abnormal growth of body tissues[3]
  • Neuroendocrine tumors (NETs): Rare tumors that can occur in various parts of the body, often causing symptoms like diarrhea and flushing (known as carcinoid syndrome)[4][5]
  • Gastrointestinal bleeding: Specifically from small blood vessel malformations called angiodysplasias[6]
  • Pancreatic fistula prevention: Used after pancreatic surgery to prevent leakage of pancreatic fluids[1]
  • Congenital hyperinsulinism: A rare genetic disorder where the pancreas produces too much insulin, leading to low blood sugar in infants[7]

How Octreotide Works

Octreotide works by mimicking the action of somatostatin, a natural hormone in the body. Its main effects include:

  • Reducing the production of certain hormones, such as growth hormone and insulin-like growth factor 1 (IGF-1)[2]
  • Slowing down the release of hormones from hormone-producing tumors[4]
  • Decreasing blood flow to the intestines, which can help reduce bleeding from angiodysplasias[6]
  • Reducing the secretion of pancreatic fluids, which can help prevent complications after pancreatic surgery[1]

Forms and Administration

Octreotide is available in different forms:

  • Short-acting form: Given as subcutaneous (under the skin) injections, usually multiple times a day[1]
  • Long-acting release (LAR) form: Given as an intramuscular injection (into a muscle) typically once every 4 weeks. This form is also known as Octreotide LAR or Sandostatin LAR[3][6]

The dosage and frequency of administration depend on the condition being treated and the patient’s response to the medication.

Effectiveness of Octreotide

Research has shown that octreotide can be effective in treating various conditions:

  • In acromegaly, it can help reduce growth hormone and IGF-1 levels, leading to improvement in symptoms[3]
  • For patients with neuroendocrine tumors, it can help control symptoms like diarrhea and flushing, and may slow tumor growth[5]
  • In gastrointestinal bleeding from angiodysplasias, it can reduce the need for blood transfusions[6]
  • For congenital hyperinsulinism, it can help maintain normal blood sugar levels in infants[7]

Potential Side Effects

Like all medications, octreotide can cause side effects. Some potential side effects include:

  • Gastrointestinal symptoms such as nausea, abdominal pain, and diarrhea
  • Gallbladder problems, including gallstones
  • Injection site reactions
  • Changes in blood sugar levels

It’s important to discuss potential side effects with your healthcare provider[2].

Ongoing Research and Future Potential

Researchers continue to study octreotide for various conditions:

  • Its potential role in slowing the progression of polycystic kidney disease (ADPKD)[8][9]
  • Its effects on the immune system in patients with neuroendocrine tumors[4]
  • Its use in preventing complications after pancreatic surgery[10]

These ongoing studies may lead to new uses for octreotide in the future, potentially benefiting more patients with various conditions.

Aspect Details
Conditions Studied Neuroendocrine tumors, Carcinoid syndrome, ADPKD, Angiodysplasia-related anemia, Acromegaly, Bronchorrhea
Administration Long-acting release (LAR) formulation, intramuscular injections every 28 days
Dosage Range 10-60 mg, depending on the condition and study protocol
Primary Outcomes Symptom reduction, disease progression slowing, quality of life improvement
Potential Benefits Reduced diarrhea and flushing, slowed kidney volume growth, decreased transfusion requirements, improved management of airway secretions
Safety Considerations Generally well-tolerated, potential side effects include gastrointestinal symptoms and gallbladder issues
Ongoing Research Evaluating efficacy in various conditions, optimizing dosage and administration protocols

FAQ

  • What is octreotide and how does it work? Octreotide is a synthetic analog of somatostatin, a hormone that regulates various bodily functions. It works by binding to somatostatin receptors, which can help inhibit the release of certain hormones and reduce symptoms in various conditions.
  • What medical conditions are being studied with octreotide in clinical trials? Clinical trials are exploring octreotide's potential in treating conditions such as neuroendocrine tumors, carcinoid syndrome, autosomal dominant polycystic kidney disease (ADPKD), gastrointestinal bleeding from angiodysplasias, acromegaly, and bronchorrhea in mechanically ventilated patients.
  • How is octreotide administered in these clinical trials? Octreotide is typically administered as a long-acting release (LAR) formulation, given as intramuscular injections every 28 days. The dosage and frequency may vary depending on the specific trial and condition being studied.
  • What are some potential benefits of octreotide treatment? Potential benefits of octreotide treatment include reducing symptoms such as diarrhea and flushing in carcinoid syndrome, slowing kidney volume growth in ADPKD, decreasing blood and iron requirements in angiodysplasia-related anemia, and managing excessive airway secretions in mechanically ventilated patients.
  • Are there any side effects associated with octreotide use? While octreotide is generally well-tolerated, some potential side effects may include gastrointestinal symptoms, gallbladder issues, and changes in blood sugar levels. The specific side effects and their frequency can vary depending on the condition being treated and the dosage used.

Ongoing Clinical Trials on Octreotide

  • Study of Lutetium-177-DOTA-TATE with octreotide LAR in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) with high disease burden

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Germany Hungary Italy The Netherlands Poland +1

  • Study of Debio 4126, a new octreotide formulation, compared to placebo in patients with acromegaly who were previously treated with somatostatin analogs

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Denmark Estonia France +10

  • Study on RYZ101 for Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors After Previous Treatment

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium France The Netherlands Spain

  • Study on the Effect of Octreotide and Lanreotide in Peptide Receptor Radionuclide Therapy for Adults with Neuroendocrine Tumors

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Continuing Somatostatin Analogues with Sunitinib, Octreotide, and Lutetium (177Lu) Oxodotreotide for Patients with Neuroendocrine Tumors

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium The Netherlands

  • Study on the Effects of Octreotide in Reducing Blood Loss During Laparoscopic Liver Surgery for Patients Undergoing Hepatectomy

    Recruiting

    1 1 1
    Investigated drugs:
    Spain

  • Study on the Effectiveness of Lutetium (177Lu) Oxodotreotide and Octreotide in Patients with Advanced GEP-NET Tumors (Grade 2 and 3)

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy The Netherlands Spain

  • Study on the Effectiveness and Safety of CAM2029 Compared to Octreotide and Lanreotide in Patients with Gastroenteropancreatic Neuroendocrine Tumors

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Belgium France Germany Hungary Italy The Netherlands +2

  • Study on Octreotide for Nutritional Recovery After Surgery in Esophageal or Gastric Cancer Patients

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

Glossary

  • Octreotide: A synthetic analog of somatostatin, used to treat various medical conditions by inhibiting the release of certain hormones and reducing symptoms.
  • Somatostatin: A hormone that regulates various bodily functions, including the release of other hormones and digestive processes.
  • Neuroendocrine tumors: Rare tumors that develop from cells of the neuroendocrine system, which produces hormones and regulates various bodily functions.
  • Carcinoid syndrome: A group of symptoms caused by certain neuroendocrine tumors, including flushing, diarrhea, and heart problems.
  • Autosomal Dominant Polycystic Kidney Disease (ADPKD): A genetic disorder characterized by the growth of numerous cysts in the kidneys, leading to kidney enlargement and potential kidney failure.
  • Angiodysplasia: Small, dilated blood vessels in the lining of the intestines that can cause gastrointestinal bleeding.
  • Acromegaly: A hormonal disorder caused by excessive production of growth hormone, leading to abnormal growth of body tissues.
  • Bronchorrhea: Excessive production of mucus in the airways, which can cause breathing difficulties and other respiratory problems.
  • Long-acting release (LAR): A formulation of a medication designed to release the active ingredient slowly over an extended period, allowing for less frequent dosing.
  • Intramuscular injection: A method of administering medication by injecting it directly into a muscle, allowing for slower absorption compared to other injection methods.

References

  1. https://clinicaltrials.gov/study/NCT03000946
  2. https://clinicaltrials.gov/study/NCT01086982
  3. https://clinicaltrials.gov/study/NCT01295060
  4. https://clinicaltrials.gov/study/NCT04129255
  5. https://clinicaltrials.gov/study/NCT04140409
  6. https://clinicaltrials.gov/study/NCT02384122
  7. https://clinicaltrials.gov/study/NCT00987168
  8. https://clinicaltrials.gov/study/NCT01377246
  9. https://clinicaltrials.gov/study/NCT06193616
  10. https://clinicaltrials.gov/study/NCT02032784